| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.
|
2011
|
1.81
|
|
2
|
Autophagy as a target for cancer therapy: new developments.
|
2012
|
1.44
|
|
3
|
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods.
|
2014
|
1.35
|
|
4
|
Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution.
|
2012
|
1.26
|
|
5
|
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.
|
2011
|
1.23
|
|
6
|
The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective.
|
2013
|
1.22
|
|
7
|
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.
|
2015
|
1.19
|
|
8
|
Computer-aided detection of colonic polyps with level set-based adaptive convolution in volumetric mucosa to advance CT colonography toward a screening modality.
|
2009
|
1.17
|
|
9
|
Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.
|
2014
|
1.17
|
|
10
|
Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives.
|
2014
|
1.13
|
|
11
|
The claudin family of proteins in human malignancy: a clinical perspective.
|
2013
|
1.10
|
|
12
|
Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.
|
2010
|
1.08
|
|
13
|
Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma.
|
2012
|
1.08
|
|
14
|
MicroRNA function and dysregulation in bone tumors: the evidence to date.
|
2014
|
1.07
|
|
15
|
MicroRNA dysregulation as a prognostic biomarker in colorectal cancer.
|
2014
|
1.05
|
|
16
|
Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer.
|
2009
|
1.05
|
|
17
|
Atypical teratoid rhabdoid tumors: a population-based clinical outcomes study involving 174 patients from the Surveillance, Epidemiology, and End Results database (1973-2010).
|
2015
|
1.04
|
|
18
|
Decitabine in the treatment of acute myeloid leukemia in elderly patients.
|
2014
|
1.03
|
|
19
|
The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses.
|
2012
|
1.02
|
|
20
|
Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.
|
2013
|
1.01
|
|
21
|
Treatment of cutaneous melanoma: current approaches and future prospects.
|
2010
|
1.01
|
|
22
|
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.
|
2013
|
1.00
|
|
23
|
AKT-independent PI3-K signaling in cancer - emerging role for SGK3.
|
2013
|
0.99
|
|
24
|
Use of capecitabine in management of early colon cancer.
|
2011
|
0.99
|
|
25
|
Cancer-associated thrombosis: clinical presentation and survival.
|
2013
|
0.98
|
|
26
|
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer.
|
2010
|
0.98
|
|
27
|
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study.
|
2014
|
0.96
|
|
28
|
3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.
|
2013
|
0.96
|
|
29
|
Cancer chemotherapy: targeting folic acid synthesis.
|
2010
|
0.95
|
|
30
|
Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin.
|
2012
|
0.94
|
|
31
|
Molecular effects of bioactive fraction of Curcuma mangga (DLBS4847) as a downregulator of 5α-reductase activity pathways in prostatic epithelial cells.
|
2014
|
0.94
|
|
32
|
New modalities of cancer treatment for NSCLC: focus on immunotherapy.
|
2014
|
0.94
|
|
33
|
Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.
|
2015
|
0.93
|
|
34
|
Inherited variation in pattern recognition receptors and cancer: dangerous liaisons?
|
2012
|
0.92
|
|
35
|
Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.
|
2014
|
0.92
|
|
36
|
The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
|
2013
|
0.91
|
|
37
|
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma.
|
2012
|
0.91
|
|
38
|
Bioimpedance and chronoamperometry as an adjunct to prostate-specific antigen screening for prostate cancer.
|
2011
|
0.91
|
|
39
|
Nedaplatin: a cisplatin derivative in cancer chemotherapy.
|
2013
|
0.90
|
|
40
|
Endoscopic endonasal approach for the treatment of a large clival giant cell tumor complicated by an intraoperative internal carotid artery rupture.
|
2013
|
0.90
|
|
41
|
Targeting autophagy in cancer management - strategies and developments.
|
2015
|
0.89
|
|
42
|
Cancer prevention, aerobic capacity, and physical functioning in survivors related to physical activity: a recent review.
|
2010
|
0.89
|
|
43
|
Treating advanced melanoma: current insights and opportunities.
|
2014
|
0.89
|
|
44
|
Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis.
|
2012
|
0.89
|
|
45
|
Reduced cancer risk in vegetarians: an analysis of recent reports.
|
2010
|
0.88
|
|
46
|
Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation.
|
2012
|
0.88
|
|
47
|
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.
|
2012
|
0.88
|
|
48
|
Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment.
|
2013
|
0.88
|
|
49
|
Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit.
|
2010
|
0.88
|
|
50
|
Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.
|
2013
|
0.88
|